

ASX ANNOUNCEMENT

BENITEC BIOPHARMA (ASX: BLT; OTC: BTEBD)

3 July 2015

RA CAPITAL SUBSTANTIAL SHAREHOLDER NOTICE

Sydney, Australia: The RA Capital substantial shareholder notice relates to shares sold on the open market by RA Capital over the past few months. This represents a trimming of RA Capital's investment in Benitec. By July 1st, the total shares sold in the period since the last 'Substantial Shareholder' filing by RA Capital reached 1,199,706 shares. These share sales over this period brought RA Capital across the 1% substantial shareholder threshold. RA Capital remains a substantial shareholder in Benitec.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT; OTC: BTEBD) which has developed a patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. For more information visit www.benitec.com.